Conagra Brands Inc vs Citius Pharmaceuticals Inc — how do they compare? Conagra Brands Inc trades at $14.93 (market cap $7.14B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M). The key difference: Conagra Brands Inc is far larger — about 356.8× Citius Pharmaceuticals Inc's market cap, and Conagra Brands Inc pays a 8.2% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CAG | CTXR | |
|---|---|---|
Market Cap | $7.14B | $20.01M |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $1.82 |
52-Week Low | $12.58 | $0.48 |
Enterprise Value | $14.20B | $16.23M |
Dividend Yield | 8.2% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Trailing returns across standard periods
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →